[Teduglutide for the treatment of patients with short bowel syndrome]
Mengarelli C, Augustovski F, Pichon-Riviere A, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L
Record ID 32015001151
Spanish
Authors' recommendations:
The evidence found on the use of teduglutide in patients with short bowel syndrome is scarce and of moderate quality. Its use enabled decreasing the required volume of parenteral nutrition, but it did not allow total independence from it. It is not approved by ANMAT (although it is by FDA and EMA). The lack of impact in quality of life, its high cost and the lack of long-term results are limiting factors against recommending its use. The US health insurance companies cover its use only in adults with diagnosed short bowel syndrome, who have required continuous parenteral nutrition more than three days a week during the last 12 months.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.iecs.org.ar/publicacion/?id=5201
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Peptides
- Gastrointestinal Agents
- Short Bowel Syndrome
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
<p>Institute for Clinical Effectiveness and Health Policy (IECS)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.